Brain-computer interface company Synchron raises $200M
New York-based Synchron, a brain-computer interface (BCI) developer, has secured $200 million in Series D funding, increasing its total capital raised to $345 million.
Funding Details
- Lead investor: Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
About Synchron's Technology
Synchron developed the Stentrode BCI, a non-surgical endovascular brain-computer interface platform designed to enhance mobility, communication, and independence for people with paralysis.
The Stentrode "is placed in the brain via a non-surgical catheter procedure and translates brain activity into digital commands by interfacing with the motor cortex through the blood vessels, recording and transmitting neural signals."
This technology enables hands-free control of digital devices and has already been implanted in 10 paralysis patients during clinical trials in Australia and the U.S.
Use of Funds
- Accelerate clinical trials and commercialization of the BCI
- Expand operations in New York, where its cognitive AI division develops models trained on brain data
- Grow its engineering hub in San Diego
Author's summary: Synchron's $200 million funding round will drive widespread adoption of its innovative, minimally invasive BCI technology, enhancing autonomy for people with paralysis.